As scientists continue to expand the utility of biomarkers in basic and applied life science research, advances in immunoassay technologies further empower these efforts by improving the way key markers of health and disease are identified, characterized, and measured in biological samples. In particular, recent advances of ultrasensitive assay platforms strive to enable researchers to better understand the importance and application of both novel and existing biomarkers by detecting them at levels never before possible. In doing so, scientists are able to more confidently draw meaningful conclusions regarding molecules important in early disease onset and characterize the modulation of efficacy and safety biomarkers in clinical trials, potentiating future advances in the development of therapeutics.
MilliporeSigma is excited to invite you to our upcoming virtual symposium on the power of Single Molecule Counting (SMC™) ultrasensitive immunoassay technology on March 31, 2021. Whether you are already working on the cutting edge of biomarker research, or are seeking to learn how immunoassays can enable your next scientific breakthrough, join our symposium to:
Dr. Tailor brings over 10 years of immunoassay platform experience in the biopharmaceutical industry. Dr. Tailor earned her Master's in Pharmacology at Kings College, London and then went on to do her Ph.D. in Biochemical Immunopharmacology at the University of London, UK. She was a Post-Doctoral Fellow in physiology and pharmacology at LSU Health Sciences, followed by faculty positions at Johns Hopkins and NIH. In 2009, Dr. Tailor moved into industry as a Field Application Scientist for Meso Scale Diagnostics and Singulex (MilliporeSigma). In 2016, Dr. Tailor was appointed the global role of SMCTM Technology and Application Lead within the Life Science Division at MilliporeSigma, where she led multiple teams globally on the utility of SMCTM technology as a bioanalytical tool for multiple research applications within industry and academia. More recently, Dr. Tailor joined the global Biology Technical Marketing group, focusing on the Immunoassay portfolio within Pharma and CROs.
Allison is a Principal Scientist at Aptevo Therapeutics in Seattle, WA, where she leads the Bioanalytical and Pharmacokinetics group. Her team focuses on the development of pharmacokinetic, immunogenicity, and biomarker assays for early preclinical to clinical stage support of ADAPTIR™ bispecific antibodies. Allison received a Master of Science degree in Cell Physiology from Case Western Reserve University in 2005. Prior to joining Aptevo, she was a Principal Scientist at Pfizer in La Jolla, CA in the BioMedicine Design department where she specialized in large molecule program management, bioanalytical assay development, and implementation of new technologies.
Sandeep Narpala is a Scientific Project Manager at the Vaccine Immunology Program (VIP), part of the Vaccine Research Center (VRC) within the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Sandeep manages the procurement of reagents, development, optimization, and qualification of novel clinical immunoassays and schedules the testing of pre-clinical and clinical trial samples conducted at VRC.
Mr. Narpala has been affiliated with the VRC/NIH since 2011 and has extensive knowledge in assay development for vaccine research on various platforms such as Meso Scale Discovery (MSD), Single Molecule Counting (SMC™) technology, and other ELISA-based platforms. Sandeep has successfully developed and qualified immunogenicity assays to assess secondary objectives in HIV and influenza vaccine clinical trials and has expertise in the development of pharmacokinetic and anti-drug antibodies assays for passive monoclonal antibody trials conducted at VRC. Before working at NIH, Mr. Narpala honed his skills working as a biologist at International Aids Vaccine Initiative (IAVI) in New York City. With his bioinformatics background, Sandeep was involved in the in-silico design of HIV immunogens using Molecular Dynamics simulations at IAVI.
Sandeep has a Masters in Bioinformatics and graduated from Northeastern University, Boston in 2009. Sandeep plans to grow as a Project Manager at VIP and is currently involved in managing and overseeing the development of immunoassays to screen new COVID-19 spike specific antibodies and multiplexed assays to detect binding COVID-19 antibodies in serosurveillance studies.
Juan J. Díaz-Mochón is a chemical biology scientist turned biotech entrepreneur and promoter of the field of liquid biopsy as a way to improve patient care. He has enjoyed a distinguished academic career in Spain, Italy, and the UK, where he spent more than 10 years. Díaz-Mochón is the author of more than 70 peer-reviewed scientific publications and is the co-inventor of 14 patents. Building on one of his inventions, in 2010, he co-founded DESTINA Genomics Ltd. in Scotland with the ambition to become a leading manufacturer and supplier of custom chemical reagents and technologies for the best nucleic acid-based biomarker assays of his class. Díaz-Mochón, together with the late CEO of DESTINA, Hugh Ilyine, promoted the incorporation of the DESTINA subsidiary in Spain. Since then, DESTINA's R & D operations have been carried out in Spain, where cheaper, more accurate and much more significant nucleic acid testing tools are being developed by more than 10 full-time employees.
Díaz-Mochón served as Chief Scientific Officer of DESTINA since its foundation and currently serves as Executive Director and CEO of DESTINA.
In 2020, DESTINA, together with Roslin Technologies Limited, incorporated VETSINA Animal Diagnostics in Scotland, a company focused on developing and commercializing new veterinary assays. Díaz-Mochón is a member of the Scientific Advisory Committee of VETSINA. In the area of nonprofit organizations, in 2017, Díaz-Mochón co-founded the International Society for Liquid Biopsy, an organization committed to advancing Liquid Biopsy and promoting a multidisciplinary approach to the diagnosis and treatment of patients based on the use of liquid. biopsies. He is currently a Board Member of the Society.
Díaz-Mochón holds a Ph.D. in Pharmacy from the University of Granada, studied as an undergraduate at the Università degli studi di Perugia and worked as a PDRA at the University of Southampton and the University of Edinburgh.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events